INDV
Indivior to Report Second Quarter 2026 Financial Results and Host Webcast
Article Summary
HOLD- Indivior Pharmaceuticals Inc. (Nasdaq: INDV) announced that it will report its second quarter 2026 financial results on August 4, 2026, at 7:00 a.m.
- EDT, followed by a live webcast presentation at 8:00 A.M.
- Indivior is the leader in long-acting injectable treatments for opioid use disorder (OUD), singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease.
- For more than 25 years, Indivior has revolutionized the science of addiction medicine developing treatments that help people move toward long-term recovery with independence and dignity.
- The webcast event and materials can be accessed on the Investor section of Indivior's website at www.indivior.com before the event begins.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 10.3% | 25% | 50.0 ptsMeets Minimum (10.3%) - Passes screener |
| EPS Growth Next 5Y ? | 18.6% | 25% | 50.0 ptsMeets Minimum (18.6%) - Passes screener |
| Target Price Upside ? | 25.4% | 20% | 75.0 ptsSignificant Upside (25.4%) - Target: $50.83 vs Current: $40.54 |
| Gross Margin % ? | 83.1% | 15% | 100.0 ptsExceptional (83.1%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -5.3% | 15% | 20.0 ptsBarely a Dip (-5.3%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About INDV
- Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.
- It develops medicines to treat substance use disorders.
- The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film.
- It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD).
- In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.
- The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026.
- Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.